Study finds deroofing and laser treatment effective against hidradenitis suppurativa

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-01-17T06:00:55+05:30 | Updated On 17 Jan 2024 6:01 AM IST

A 12-month observational cohort study published in the Health Technology Assessment analyzed deroofing and laser treatment effective for Hidradenitis Suppurativa (HS), a chronic inflammatory skin disease. Hidradenitis Suppurativa is represented by recurrent inflammatory lesions and skin tunnels, primarily in areas such as the axilla.

The Treatment of Hidradenitis Suppurativa Evaluation Study included a total of 151 adult participants with active HS which was not adequately controlled by current treatments. Oral doxycycline, oral clindamycin and rifampicin, laser treatment, deroofing and conventional surgery were the five treatment options assessed.

The results from this research revealed that laser treatment had the highest proportion (69%) of participants willing to receive treatment followed by deroofing (58%), conventional surgery (54%), the combination of oral clindamycin and rifampicin (44%), and doxycycline (37%). Laser treatment was the first choice for 41% of participants which showed positive opportunities for future interventions.

The study highlighted the influence of clinicians on the willingness of participants to undergo treatments. The Treatment of Hidradenitis Suppurativa Evaluation Study established deroofing and laser treatment as viable options for HS in the UK and also laid the groundwork for future randomized controlled trials.

This study demonstrated high follow-up rates of 89% and 83% after 3 and 6 months, respectively. This comprehensive approach included daily pain score text messages for 110 participants which highlighted the evolving dynamics of pain management during the research.

This consensus workshop prioritized laser treatment and deroofing as key interventions for future randomized controlled trials by potentially opening new avenues for effective HS management in the UK.

Reference;

Ingram, J. R., Bates, J., Cannings-John, R., Collier, F., Gibbons, A., Harris, C., Hood, K., Howells, L., Howes, R., Leighton, P., Riaz, M., Rodrigues, J., Stanton, H., Thomas, K. S., & Thomas-Jones, E. (2023). Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study. In Health Technology Assessment (pp. 1–107). National Institute for Health and Care Research. https://doi.org/10.3310/hwnm2189

Health Technology Assessmenthidradenitis suppurativalaser treatment

Source : Health Technology Assessment

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751